SP0202-VII

SP0202-VII is a formulation of **SP0202**, a 21-valent **pneumococcal conjugate vaccine** (PCV21) currently in clinical development. It is designed to provide **expanded protection against Streptococcus pneumoniae infections** by incorporating polysaccharide antigens from 21 distinct serotypes, conjugated to two different protein carriers—tetanus toxoid and CRM197 (a non-toxic mutant of diphtheria toxin)[1][3]. Its mechanism involves presenting conjugated polysaccharides to the immune system, provoking a T-dependent immune response, leading to production of serotype-specific IgG antibodies that promote bacterial opsonization and complement-dependent phagocytosis[1]. SP0202-VII is one of several formulations evaluated in clinical trials, notably in healthy adults aged 50 to 84 years, aiming to demonstrate safety and immunogenicity compared to licensed comparators (Prevnar 13 and Pneumovax 23)[3].

Other names

SP-0202-VIISP0202-VIISP 0202-VIISP0202 VIISP-0202 VIISP 0202 VII